Bayesian dose selection design for a binary outcome using restricted response adaptive randomization

BACKGROUND: In phase II trials, the most efficacious dose is usually not known. Moreover, given limited resources, it is difficult to robustly identify a dose while also testing for a signal of efficacy that would support a phase III trial. Recent designs have sought to be more efficient by explorin...

Descripción completa

Detalles Bibliográficos
Autores principales: Meinzer, Caitlyn, Martin, Renee, Suarez, Jose I.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591573/
https://www.ncbi.nlm.nih.gov/pubmed/28886745
http://dx.doi.org/10.1186/s13063-017-2004-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5591573/
https://www.ncbi.nlm.nih.gov/pubmed/28886745
http://dx.doi.org/10.1186/s13063-017-2004-6

Ejemplares similares